Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in Mature T-cell and NK-cell Neoplasms
CTR20171387Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in peripheral T-cell lymphoma (PTCL), extranodal natural killer/T-cell lymphoma (ENKTL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), sponsored by BeiGene. Started Jan 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
peripheral T-cell lymphoma (PTCL)extranodal natural killer/T-cell lymphoma (ENKTL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on CTR20171387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171387.